Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PURINETHOL vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Acute lymphoblastic leukemia (ALL) maintenance therapy (FDA-approved),Chronic myeloid leukemia (CML) (off-label),Inflammatory bowel disease (Crohn's disease, ulcerative colitis) (off-label),Autoimmune hepatitis (off-label)
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily metabolized by xanthine oxidase (XO) to 6-thiouric acid (inactive), and via thiopurine methyltransferase (TPMT) to 6-methylmercaptopurine (inactive). Activity of TPMT and NUDT15 affects toxicity. Allopurinol inhibits XO, leading to increased mercaptopurine levels.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 19% bound to plasma proteins, primarily albumin.
47% bound to human plasma proteins, primarily albumin.
Volume of distribution is 0.9 L/kg, indicating distribution into total body water.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Oral bioavailability is highly variable, ranging from 5% to 37% (mean approximately 16%), due to extensive first-pass metabolism.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
GFR 50-80 m L/min: reduce dose by 25-50%. GFR 10-50 m L/min: reduce dose by 50-75%. GFR <10 m L/min: administer 50% of normal dose every 48 hours or consider alternative.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Induction: 50-75 mg/m² orally once daily. Maintenance: 50-75 mg/m² orally once daily. Adjust based on tolerance and disease response.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
Start at lower end of dosing range (1.5 mg/kg/day). Monitor renal function and hematologic parameters closely. Reduce dose if significant renal impairment present.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
Severe myelosuppression, especially with TPMT or NUDT15 deficiency. The drug is myelotoxic; fatal myelosuppression can occur. Monitor blood counts frequently.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Myelosuppression: monitor CBCs regularly; reduce dose if severe.,TPMT/NUDT15 deficiency: increased risk of severe myelosuppression; consider testing before therapy.,Hepatotoxicity: monitor liver function tests; can cause hepatic veno-occlusive disease.,Immunosuppression: increased risk of infections.,Carcinogenicity: risk of secondary malignancies, especially with prolonged use.,Pregnancy: Category D; may cause fetal harm.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Hypersensitivity to mercaptopurine,Prior resistance to mercaptopurine (ineffective),Severe myelosuppression (unless benefits outweigh risks),Concomitant use with allopurinol (unless dose-adjusted due to toxicity risk),Pregnancy (absolute contraindication in some contexts)
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice as they may increase drug levels. May decrease the effectiveness of warfarin; monitor INR if consuming vitamin K-rich foods. Alcohol consumption should be minimized due to potential hepatotoxicity.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intrauterine growth restriction, preterm delivery, and fetal myelosuppression. Overall, considered teratogenic in humans; avoid use unless benefit outweighs risk.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
Present in breast milk in low concentrations. M/P ratio not established. Potential for infant myelosuppression and immunosuppression. Contraindicated in breastfeeding or use with caution; monitor infant for neutropenia and thrombocytopenia.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
Increased clearance during pregnancy may require dose adjustment. Monitor therapeutic drug levels (if available) and clinical response. Dose may need to be increased by up to 50% in second and third trimesters; post-partum reduce dose to pre-pregnancy levels.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Purinethol (6-mercaptopurine) is a prodrug converted to active thioguanine nucleotides. Co-administration with allopurinol requires a 65-75% dose reduction of Purinethol due to inhibition of xanthine oxidase. TPMT genotyping or phenotyping is recommended prior to initiation to avoid severe myelosuppression. Monitor CBC and liver enzymes regularly. Avoid live vaccines during therapy.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Take this medication exactly as prescribed, usually once daily.,Do not take with allopurinol unless specifically instructed by your doctor, as it may increase side effects.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or jaundice immediately.,Avoid live vaccines (e.g., MMR, varicella) while on this medication.,Drink plenty of fluids to prevent kidney stones from uric acid accumulation.,If you miss a dose, do not double the next dose; take it as soon as remembered if within 12 hours of scheduled time.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PURINETHOL vs CLOLAR, answered by our medical review team.
PURINETHOL is a Antineoplastic Agent that works by Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PURINETHOL and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PURINETHOL is: 1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PURINETHOL and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PURINETHOL is classified as Category C. First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intraut. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.